Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chia Tai Tianqing Pharmaceutical (Guangzhou) is a key subsidiary of Sino Biopharmaceutical, one of China's largest and most innovative pharmaceutical conglomerates. Based in Guangzhou, the company serves as a major hub for the group's research, development, and manufacturing, with a specialized focus on liver disease, oncology, and respiratory health. It is recognized for transitioning from a leading generic manufacturer to an innovation-driven biopharmaceutical player, supported by a robust pipeline of small molecules and biologics. The company's portfolio includes blockbuster treatments for hepatitis and various solid tumors, leveraging advanced GMP-certified facilities. As part of the broader CTTQ group, it maintains extensive R&D capabilities and a strong commercial presence across the Asia-Pacific region.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chia Tai Tianqing Pharmaceutical (Guangzhou).